Pretreatment counts of 5 CTCs per 7.5 mL of blood or higher correlated with shorter survival compared with lower counts among men with metastatic castration-resistant prostate cancer treated with radium-223, a study found.
Copy number loss of 17q22 was associated with enzalutamide resistance and shorter overall survival among men with metastatic castration-resistant prostate cancer.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
In a small study, radiation therapy directed at the primary tumor in men with metastatic castration-resistant prostate cancer was significantly associated with improved cancer-specific and overall survival.
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.
Men with metastatic castration-resistant prostate cancer with predominantly bone metastases who receive more than 4 dose of radium-223 have significantly improved overall survival than those who receive 4 or fewer doses, a study found.
A new analysis of men in the CARD study showed that cabazitaxel improved pain response and decreased the likelihood of pain progression compared with either abiraterone or enzalutamide.
In the TITAN trial, health-related quality of life did not worsen with the addition of apalutamide to ADT versus placebo for patients with metastatic castration-sensitive prostate cancer.
In mCRPC patients previously treated with docetaxel and either abiraterone or enzalutamide, third-line therapy with cabazitaxel offered longer imaging-based progression-free survival and overall survival compared with switching patients to the other antiandrogen, the CARD study found.
In the phase 3 ARAMIS trial, darolutamide, a nonsteroidal androgen receptor inhibitor, significantly delayed development of metastasis in men with nonmetastatic castration-resistant prostate cancer.
